Search
Search
Top Menu
About
Philosophy
Vision & Strategy
Group Code of Conduct
Astellas Pharma Israel
Policies & Position Statements
Support for Medical Education
Top Menu
Therapy Areas
Therapy Areas
Urology
Oncology / Haematology
Transplantation
Astellas Products
BETMIGA™ (mirabegron)
MYCAMINE™ (micafungin sodium)
RIBOMUSTIN™ (bendamustine)
XTANDI™ (enzalutamide)
XOSPATA™ (gilteritinib)
ADVAGRAF™ (tacrolimus prolonged release)
PROGRAF™ (tacrolimus)
PADCEV™
Top Menu
Innovation
Clinical Trials
Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…
Read More
R & D
Clinical Trials
Approach
Ethics & Principles
Pipeline
Investigator Sponsored Research
Top Menu
Sustainability
Access to Health
Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…
Read More
Making an Impact
Environment
CSR-Based Management
ISO26000
Materiality
Access to Health
Ethics & Compliance
Transparency
Supporting-patients
Modern Slavery Act
Gender Pay Gap Report
Global Sustainability Policy
Top Menu
News
Media Contacts
The Astellas Corporate Communications team will respond to calls and emails from journalists. For general media enquiries, please email contact_uk...
Read More
News
Media Contacts
Social Media Code of Conduct
Common header menu
CONTACT US
CAREERS
WORLDWIDE
ISRAEL
WORLDWIDE - ISRAEL
English
עברית
Latest
Pause
Next
Astellas Pharma Israel
Find out more
Urology
Find out more
Oncology / Haematology
Find out more
1
2
3
Making an Impact
Find out more
Therapy Areas
Find out more
NON_2021_0008_IL
Menu
